Galderma Achieves Record 2 B USD Net Sales for a Six-Month Period in H1 2023, as It Continues to Demonstrate Leading Execution and Innovation Capabilities in Dermatology

2023年07月31日 11:04:49 来自: (0)参与

ZUG, Switzerland--(BUSINESS WIRE)--Galderma:

  • Galderma maintained strong momentum across all product categories reaching 2,003 M USD net sales in H1 2023, up 6.9% year-on-year on a constant currency basis
  • Growth primarily driven by Dermatological Skincare and Therapeutic Dermatology; Injectable Aesthetics continued to grow driven by double-digit performance in both Neuromodulators and Biostimulators despite softening in the Filler market and a high comparative base for the product category in 2022 following a post-COVID rebound
  • Delivered significant Core EBITDA margin expansion in H1 2023, with a Core EBITDA of 450 M USD and margin of 22.5% compared to 21.0% for full year 2022
  • On track to deliver on 2023 full-year revenue and profitability guidance of 6-9% constant currency net sales growth and 200-300 bps Core EBITDA margin expansion versus 2022
  • Showcased best-in-class innovation capabilities across its leading dermatology portfolio, including positive phase III data for nemolizumab in adult patients with prurigo nodularis, along with FDA approvals and major launches in Injectable Aesthetics and Dermatological Skincare
  • Private placement of over 1 B USD raised for newly issued shares, with proceeds used to strengthen the balance sheet and further accelerate Galderma’s organic growth momentum

 

“Galderma sustained its growth momentum in the first half of 2023 driven by a laser focus on commercial execution and by premium positioning in attractive, high-growth markets. Galderma continues to demonstrate its commitment to bringing science-based, premium products to consumers, patients, and healthcare professionals, with new FDA approvals and new product launches in the first half of 2023. We also shared further positive data that underscores the strength of our differentiated innovation pipeline. I am delighted to see our unique, integrated dermatology strategy go from strength to strength, as we continue to deliver on our ambition to become the leader in dermatology.”

 

FLEMMING ØRNSKOV, M.D., MPH

CHIEF EXECUTIVE OFFICER

 
相关新闻
天涯网友:不要骗我了°
评论:我说过我爱你。没说我只爱你。

天猫网友:THOMAS 《死亡诗社》
评论:有些人,认真的让你心疼,有些人,欠扁的让你牙疼

本网网友:私欲° 7/m
评论:有人说我懒得抽筋,其实我连抽筋都懒得抽

猫扑网友:清高 Demon,
评论:小时候哭着哭着就笑了,长大后笑着笑着就哭了。

淘宝网友:Terminalぃ句点
评论:世界上最疼痛的话是:“我爱你,但是……”。世界上最甜蜜的话是:“……但是,我爱你”。

其它网友:〆心臟在跳動
评论:暧昧的本质是激情,而爱情的本质是平淡。

百度网友:圈套  Easuysug▍
评论:在身材这个问题上,我是坚决不会承认自己是一个粗人的。

腾讯网友:忘了爱° Toro
评论:职场三定律:要么狠 要么忍 要么滚;成功三要素:一是坚持,二是不要脸,三是坚持不要脸

凤凰网友:Cool| 卡其布
评论:梦想是用来破灭的,不是用来实现的,因为在现实面前,它就是一个屁。

网易网友:魂牵于心  7mr°
评论:真正能阻止离婚的婚姻法是:离婚后房子归国家!

新闻转自网络媒体,如有侵权,请与我们联系:1160322105@qq.com责编:admin